Hoeg J M, Edge S B, Demosky S J, Starzl T E, Triche T, Gregg R E, Brewer H B
Biochim Biophys Acta. 1986 May 21;876(3):646-57. doi: 10.1016/0005-2760(86)90054-8.
The profoundly elevated concentrations of low-density lipoproteins (LDL) present in homozygous familial hypercholesterolemia lead to symptomatic cardiovascular disease and death by early adulthood. Studies conducted in nonhepatic tissues demonstrated defective cellular recognition and metabolism of LDL in these patients. Since mammalian liver removes at least half of the LDL in the circulation, the metabolism of LDL by cultured hepatocytes isolated from familial hypercholesterolemic homozygotes was compared to hepatocytes from normal individuals. Fibroblast studies demonstrated that the familial hypercholesterolemic subjects studied were LDL receptor-negative (less than 1% normal receptor activity) and LDL receptor-defective (18% normal receptor activity). Cholesterol-depleted hepatocytes from normal subjects bound and internalized 125I-labeled LDL (Bmax = 2.2 micrograms LDL/mg cell protein). Preincubation of normal hepatocytes with 200 micrograms/ml LDL reduced binding and internalization by approx. 40%. In contrast, 125I-labeled LDL binding and internalization by receptor-negative familial hypercholesterolemic hepatocytes was unaffected by cholesterol loading and considerably lower than normal. This residual LDL uptake could not be ascribed to fluid phase endocytosis as determined by [14C]sucrose uptake. The residual LDL binding by familial hypercholesterolemia hepatocytes led to a small increase in hepatocyte cholesterol content which was relatively ineffective in reducing hepatocyte 3-hydroxy-3-methylglutaryl-CoA reductase activity. Receptor-defective familial hypercholesterolemia hepatocytes retained some degree of regulatable 125I-labeled LDL uptake, but LDL uptake did not lead to normal hepatocyte cholesterol content or 3-hydroxy-3-methylglutaryl-CoA reductase activity. These combined results indicate that the LDL receptor abnormality present in familial hypercholesterolemia fibroblasts reflects deranged hepatocyte LDL recognition and metabolism. In addition, a low-affinity, nonsaturable uptake process for LDL is present in human liver which does not efficiently modulate hepatocyte cholesterol content or synthesis.
纯合子家族性高胆固醇血症患者体内低密度脂蛋白(LDL)浓度显著升高,会导致在成年早期出现症状性心血管疾病并死亡。在非肝脏组织中进行的研究表明,这些患者的细胞对LDL的识别和代谢存在缺陷。由于哺乳动物肝脏可清除循环中至少一半的LDL,因此将从家族性高胆固醇血症纯合子中分离出的培养肝细胞对LDL的代谢与正常个体的肝细胞进行了比较。成纤维细胞研究表明,所研究的家族性高胆固醇血症患者为LDL受体阴性(受体活性低于正常的1%)和LDL受体缺陷(受体活性为正常的18%)。来自正常受试者的胆固醇耗竭肝细胞能结合并内化125I标记的LDL(Bmax = 2.2微克LDL/毫克细胞蛋白)。正常肝细胞与200微克/毫升LDL预孵育后,结合和内化减少约40%。相比之下,受体阴性的家族性高胆固醇血症肝细胞对125I标记的LDL的结合和内化不受胆固醇负荷的影响,且显著低于正常水平。通过[14C]蔗糖摄取测定,这种残余的LDL摄取不能归因于液相内吞作用。家族性高胆固醇血症肝细胞对LDL的残余结合导致肝细胞胆固醇含量略有增加,但在降低肝细胞3-羟基-3-甲基戊二酰辅酶A还原酶活性方面相对无效。受体缺陷的家族性高胆固醇血症肝细胞保留了一定程度的可调节的125I标记的LDL摄取,但LDL摄取并未导致正常的肝细胞胆固醇含量或3-羟基-3-甲基戊二酰辅酶A还原酶活性。这些综合结果表明,家族性高胆固醇血症成纤维细胞中存在的LDL受体异常反映了肝细胞对LDL的识别和代谢紊乱。此外,人类肝脏中存在一种对LDL的低亲和力、不饱和摄取过程,该过程不能有效调节肝细胞胆固醇含量或合成。